Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) Operating Expenses (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Operating Expenses for 17 consecutive years, with $2.1 million as the latest value for Q1 2026.

  • Quarterly Operating Expenses rose 120.58% to $2.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $5.4 million through Jan 2026, down 17.18% year-over-year, with the annual reading at $4.4 million for FY2025, 48.62% down from the prior year.
  • Operating Expenses for Q1 2026 was $2.1 million at PharmaCyte Biotech, up from $1.4 million in the prior quarter.
  • The five-year high for Operating Expenses was $3.2 million in Q2 2024, with the low at $848305.0 in Q3 2025.
  • Average Operating Expenses over 5 years is $1.5 million, with a median of $1.4 million recorded in 2023.
  • The sharpest move saw Operating Expenses soared 250.52% in 2024, then plummeted 67.09% in 2025.
  • Over 5 years, Operating Expenses stood at $2.3 million in 2022, then crashed by 39.21% to $1.4 million in 2023, then fell by 21.53% to $1.1 million in 2024, then increased by 24.41% to $1.4 million in 2025, then skyrocketed by 53.93% to $2.1 million in 2026.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $2.1 million, $1.4 million, and $848305.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.